ArticleDiscover oncology2025
Prediction of bone or lung metastasis in prostate cancer using machine learning: a SEER-based study with external validation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) often metastasizes to bone or lung, leading to poor prognosis and higher mortality. Early identification of patients at high risk for metastasis is critical for improving treatment outcomes. However, current prediction models are limited in accuracy and generalizability. This study aimed to develop and validate machine learning models to predict bone and/or lung metastasis in PCa patients, using data from both the SEER database and an external cohort.
methodsData from 56,107 PCa patients in the SEER database (2018–2021) were analyzed, with feature selection performed using LASSO regression, identifying variables such as Gleason score, PSA levels, and N stage. Six machine learning models were constructed, including XGBoost, Random Forest, and Logistic Regression. The SMOTE technique was applied to address data imbalance, and the models were externally validated using a cohort of 201 patients from the First Affiliated Hospital of Nanchang University.
resultsIn the SEER cohort, 2868 (5.1%) patients had bone and/or lung metastasis, while 53,239 (94.9%) showed no evidence of metastasis. The external validation cohort, consisting of 201 patients, had a significantly higher metastatic rate, with 51 (25.4%) patients presenting with bone and/or lung metastasis. XGBoost showed superior performance, achieving an AUC of 0.979 in the SEER training set and 0.924 in the external validation cohort. Key predictors were Gleason score, PSA, and N stage. The model correctly identified 2768 metastatic cases (true positives) and 52,712 non-metastatic cases (true negatives). Feature importance analysis confirmed Gleason score and PSA as the most significant predictors. In external validation, the model maintained high accuracy, sensitivity, and specificity, confirming its robustness and generalizability across different patient populations.
conclusionXGBoost proved to be a highly accurate tool for predicting bone and/or lung metastasis in PCa patients. Incorporating this model into clinical practice could improve early detection of high-risk patients, enabling more personalized and timely interventions, ultimately enhancing patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.